-
NMPA Announcement on the Revision of the Package Insert of the Vitamin B6 Injection
2021-07-27
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, NMPA decided to modify the items of [Adverse reactions] and [Contraindications] in the package inserts of Vitamin B6 injection.
-
NMPA Announcement on the Revision of the Package Insert of the Propranolol Tablets
2021-07-20
The NMPA decided to modify the items of [Precautions] in the package inserts of propranolol tablets. On July 15, relevant issues are hereby announced as follows.
-
NMPA Announcement on Issuing 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices
2021-07-15
The NMPA has organized to formulate the 6 Guidance including the Guidance for Nomenclature of the Generic Names of Medical Rehabilitation Devices, which are issued on July 12.
-
NMPA Announcement on Guidance for the Classification Defining of AI-Based Medical Software Products
2021-07-08
The NMPA has organized to formulate the Principles for the Classification Defining of AI-Based Medical Software Products, which was issued on July 1.
-
NMPA Announcement on the Revision of the Package Insert of Metoclopramide
2021-07-05
In accordance with the results of adverse drug reaction evaluation, to further protect drug safety for the people, the NMPA decided to modify the items of [Adverse reactions], [Contraindications] and [Precautions] in the package inserts of Metoclopramide.
-
NMPA Announcement on Issuing 2 Guidance including the Technical Review Guidance for the Registration of Vision Screeners and Mammography Systems
2021-06-29
The NMPA organized to formulation of the Guidelines for Technical Review of Vision Screener Registration and the Guidelines for Technical Review of Mammography System Registration, which were published on June 24.
